UK's Genus falls to bottom of mid-cap index on FY25 forecast
** Shares of animal genetics firm Genus GNS.L down 5.2% at 1,806 pence, top loser on the FTSE mid-cap index .FTMC
** Co sees FY24 adjusted pre-tax profit in line with market view, between 58 mln pounds ($75.43 mln) and 61 mln pounds
** Expects FY25 adjusted operating profit to be lower than previous assumptions
** Says volume remained lower at its genetics division ABS in H2 due to weak demand in several countries, particularly in China and Brazil
** Operational gearing and currency fluctuations mean that co expects ABS' profits to reduce by about 4 mln pounds in FY24 to 14 mln pounds, despite about 6 mln pounds of cost reductions - Peel Hunt
** Including session's move, stock down about 17% YTD
($1 = 0.7689 pounds)
Reporting by DhanushVignesh Babu in Bengaluru
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
